Latest Strategic Acquisition News

Eureka Group Holdings Limited has reported a robust financial year ending June 2025, with net profit soaring 51.9% and a strategic portfolio expansion in seniors and affordable rental accommodation.

Qube Holdings delivered a robust FY25 performance with underlying revenue up 27.3% and a 7.1% dividend increase, despite a significant impairment of its MITCo investment. The company’s diversified logistics and grain trading operations powered growth amid industrial and weather challenges.

Sonic Healthcare reported solid FY2025 results with revenue up 7.6% and a steady profit increase, while declaring a 63-cent final dividend. The company’s recent German acquisition and ongoing synergy efforts set the stage for robust earnings growth in FY2026.

Qube Holdings has reported a landmark FY25 with underlying revenue soaring 27.3% to $4.46 billion and earnings rising across all key metrics, despite industrial action and adverse weather disruptions.

Peter Warren Automotive Holdings reported a steady FY25 underlying profit before tax of $22.3 million, maintaining revenue despite a challenging new car market and declaring a final dividend. The group’s strategic focus on cost control, inventory discipline, and acquisitions underpinned its resilience.

Netwealth Group Limited reported a standout FY2025 with net profit rising nearly 40% and funds under administration climbing 28%, underpinning a 37.5% increase in dividends. Strategic fintech acquisitions and robust governance enhancements position the company for sustained growth.

Qube Holdings Limited reported robust FY25 underlying revenue growth of 27%, driven by strong performances in its Logistics & Infrastructure and Ports & Bulk divisions, while declaring a 71% increase in full-year dividends. Despite challenges including industrial action and weather disruptions, Qube expects continued earnings growth in FY26 supported by strategic acquisitions and operational resilience.

Ridley Corporation reported solid FY25 results with EBITDA up 8.6% to $97.8 million and NPAT rising 8.7% to $43.3 million, underpinned by strategic acquisitions and disciplined capital management.

Redox Limited reported a 9.4% increase in FY25 revenue to $1.244 billion driven by volume growth and strategic acquisitions, while profits declined amid inflationary pressures. The company declared a final dividend of 6.5 cents per share and maintains zero net debt.

Telix Pharmaceuticals reported a robust 63% year-over-year revenue increase in H1 2025, driven by strong sales of its precision medicine products and strategic acquisitions. The company is advancing multiple late-stage clinical trials and expanding its global manufacturing footprint.

Redox Ltd reported a robust 9.4% increase in revenue for FY25, supported by strong volume growth and three strategic acquisitions, despite margin compression and a challenging macroeconomic backdrop.

Telix Pharmaceuticals reported a robust 63% revenue increase in H1 2025, driven by commercial growth and strategic investments, while advancing key clinical trials and maintaining full-year guidance.